The Eversense CGM system demonstrated greater than 93% accuracy of glucose readings from 90 contributors with diabetes in a brand new trial.
The system consists of an implantable sensor which lasts for 90 days and measures glucose ranges from interstitial fluid beneath the pores and skin floor.
The Eversense CGM was assessed as a part of the PRECISE II examine, with researchers primarily monitoring how glucose readings in comparison with reference values inside comparable ranges.
The CGM’s excessive accuracy was complemented by its beneficial security profile, measured by how simply and efficiently the device might be inserted and eliminated, and what number of procedure-related opposed occasions occurred.
The outcomes confirmed that clinicians with restricted to no surgical expertise might safely insert and take away the CGM following coaching. Only one severe opposed occasion was reported resulting from sensor insertion or removing.
Due to the CGM’s 93% accuracy and general security, Satish Garg, MD, editor-in-chief of Diabetes Technology &Therapeutics, the journal in which the outcomes seem, believes there must be elevated optimism concerning the way forward for CGMs.
“Continuous glucose monitoring is becoming standard of care especially for insulin-requiring patients with diabetes,” mentioned Dr Garg. “Eversense, if approved by the FDA, will become the first implantable CGM system for use lasting at least three months.”
First creator Mark Christiansen, MD, Leslie Klaff, MD, and colleagues added: “The outcomes from this examine exhibit that the usage of a long-term, 90-day, implantable steady glucose sensor is correct and protected with excessive charges of adherence to make use of.
“Additional medical research will likely be required to guage the accuracy and usability of the Eversense CGM system amongst pediatrics, with lowered calibration frequency, and for prolonged durations via 180 days.”
